Merck: A Post-2028 Slowdown Doesn't Kill The Long-Term Thesis

Core Insights - Merck (MRK) is heavily reliant on a drug whose patent is set to expire around 2028, raising concerns about future revenue streams [1] - The company faces significant uncertainties in its pipeline and R&D expenses, which could impact its growth potential [1] - There is a noted dependence on government regulations and policies, adding another layer of risk to the company's operations [1]